Randomized noninferiority trial of dihydroartemisinin-piperaquine compared with sulfadoxine-pyrimethamine plus amodiaquine for seasonal malaria chemoprevention in Burkina Faso

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 4387-4396

  Zongo, Issaka ^a,b   Milligan, Paul ^b   Compaore, Yves Daniel ^a   Some, A Fabrice ^a   Greenwood, Brian ^b   Tarning, Joel ^c,e   Rosenthal, Philip J ^f   Sutherland, Colin ^b   Nosten, Francois ^c,d   Ouedraogo, Jean Bosco ^a  

^a Institut de Recherche en Sciences de la Santé   (Burkina Faso)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c MAHIDOL UNIVERSITY   (Thailand)

^d SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; FOLIC ACID ANTAGONIST; HEMOGLOBIN; MOLECULAR MARKER; PYRIMETHAMINE PLUS SULFADOXINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; DRUG COMBINATION; FANASIL, PYRIMETHAMINE DRUG COMBINATION; PIPERAQUINE; PYRIMETHAMINE; QUINOLINE DERIVATIVE; SULFADOXINE;

ABDOMINAL PAIN; ARTICLE; CHEMOPROPHYLAXIS; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; FEMALE; FEVER; FOLLOW UP; GAMETOCYTE; HAPLOTYPE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFANT; JAUNDICE; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALARIA; MALE; MEDICATION COMPLIANCE; MICROSCOPY; NAUSEA; OUTCOME ASSESSMENT; PARASITEMIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT DURATION; UNDERWEIGHT; VOMITING; BURKINA FASO; CASE CONTROL STUDY; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; PRESCHOOL CHILD; PROCEDURES; SEASON;

AMODIAQUINE; ANTIMALARIALS; ARTEMISININS; BURKINA FASO; CASE-CONTROL STUDIES; CHEMOPREVENTION; CHILD, PRESCHOOL; DRUG COMBINATIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; MALARIA; MALE; PYRIMETHAMINE; QUINOLINES; SEASONS; SULFADOXINE;

EID: 84940183660     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04923-14     Document Type: Article

References (32)

1. WHO. 2011. World malaria report. World Health Organization, Geneva, Switzerland.
2. Ministère de la Santé, Burkina Faso. 2011. Annuaire statistique. Ministère de la Santé, Ougadougou, Burkina Faso.
3. Konate AT, Yaro JB, Ouedraogo AZ, Diarra A, Gansane A, Soulama I, Kangoye DT, Kabore Y, Ouedraogo E, Ouedraogo A, Tiono AB, Ouedraogo IN, Chandramohan D, Cousens S, Milligan PJ, Sirima SB, Greenwood B, Diallo DA. 2011. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial. PLoS Med 8:e1000408. http://dx.doi.org/10.1371/journal.pmed.1000408.
4. WHO. 2012. WHO policy recommendation: seasonal malaria chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa. WHO, Geneva, Switzerland. http://www.who.int/malaria/publications/atoz/who-smc-policy-recommendation/en/index.html.
5. WHO. 2012. Seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine in children, a field guide. WHO, Geneva, Switzerland. http://apps.who.int/iris/bitstream/10665/85726/1/9789241504737-eng.pdf.
6. Ahmed T, Sharma P, Gautam A, Varshney B, Kothari M, Ganguly S, Moehrle JJ, Paliwal J, Saha N, Batra V. 2008. Safety, tolerability, and single- and multiple-dose pharmacokinetics of piperaquine phosphate in healthy subjects. J Clin Pharmacol 48:166. http://dx.doi.org/10.1177/0091270007310384.
7. Tarning J, Lindegardh N, Annerberg A, Singtoroj T, Day NP, Ashton M, White NJ. 2005. Pitfalls in estimating piperaquine elimination. Antimicrob Agents Chemother 49:5127-5128. http://dx.doi.org/10.1128/AAC.49.12.5127-5128.2005.
8. Cisse B, Cairns M, Faye E, NDiaye O, Faye B, Cames C, Cheng Y, NDiaye M, Lô AC, Simondon K, Trape J-F, Faye O, NDiaye JL, Gaye O, Greenwood B, Milligan P. 2009. Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. PLoS One 4:e7164. http://dx.doi.org/10.1371/journal.pone.0007164.
9. Bojang K, Akor F, Bittaye O, Conway D, Bottomley C, Milligan P, Greenwood B. 2010. A randomised trial to compare the safety, tolerability and efficacy of three drug combinations for intermittent preventive treatment in children. PLoS One 5:e11225. http://dx.doi.org/10.1371/journal.pone.0011225.
10. Nankabirwa J, Cundill B, Clarke S, Kabatereine N, Rosenthal PJ, Dorsey G, Brooker S, Staedke SG. 2010. Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, place-bocontrolled trial in Ugandan schoolchildren. PLoS One 5:e13438. http://dx.doi.org/10.1371/journal.pone.0013438.
11. Lwin KM, Phyo AP, Tarning J, Hanpithakpong W, Ashley EA, Lee SJ, Cheah P, Singhasivanon P, White NJ, Lindegardh N, Nosten F. 2012. Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria. Antimicrob Agents Chemother 56:1571-1577. http://dx.doi.org/10.1128/AAC.05877-11.
12. Mayxay M, Thongpraseuth V, Khanthavong M, Lindegardh N, Barends M, Keola S, Pongvongsa T, Phompida S, Phetsouvanh R, Stepniewska K, White NJ, Newton PN. 2010. A phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. Am J Trop Med Hyg 83:1221-1229. http://dx.doi.org/10.4269/ajtmh.2010.10-0276.
13. Song J, Socheat D, Tan B, Seila S, Xu Y, Ou F, Sokunthea S, Sophorn L, Zhou C, Deng C, Wang Q, Li G. 2011. Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area. Malar J 10:231. http://dx.doi.org/10.1186/1475-2875-10-231.
14. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Lankoande M, Ouedraogo JB, Rosenthal PJ. 2007. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis 45:1453-1461. http://dx.doi.org/10.1086/522985.
15. Menan H, Faye O, Same-Ekobo A, Oga AS, Faye B, Kiki Barro CP, Kuete T, N'diaye JL, Vicky AM, Tine R, Yavo W, Kane D, Kassi KF, Kone M. 2011. Comparative study of the efficacy and tolerability of dihydroartemisinin-piperaquine-trimethoprim versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal. Malar J 10:185. http://dx.doi.org/10.1186/1475-2875-10-185.
16. Nambozi M, Van Geertruyden J-P, Hachizovu S, Chaponda M, Mukwamataba D, Mulenga M, Ubben D, D'Alessandro U. 2011. Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malar J 10:50. http://dx.doi.org/10.1186/1475-2875-10-50.
17. Tarning J, Zongo I, Somé FA, Rouamba N, Parikh S, Rosenthal PJ, Hanpithakpong W, Jongrak N, Day NP, White NJ, Nosten F, Ouedraogo JB, Lindegardh N. 2012. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther 91:497-505. http://dx.doi.org/10.1038/clpt.2011.254.
18. Salman S, Page-Sharp M, Batty KT, Kose K, Griffin S, Siba PM, Ilett KF, Mueller I, Davis TM. 2012. Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother 56:3288-3297. http://dx.doi.org/10.1128/AAC.06232-11.
19. Hung TY, Davis TM, Ilett KF, Karunajeewa H, Hewitt S, Denis MB, Lim C, Socheat D. 2004. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol 57:253-262.
20. WorldWide Antimalarial Resistance Network (WWARN) DP Study Group. 2013. The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med 10:e1001564. http://dx.doi.org/10.1371/journal.pmed.1001564.
21. Gadalla NB, Abdallah TM, Atwal S, Sutherland CJ, Adam I. 2013. Selection of pfdhfr/pfdhps alleles and declining artesunate/sulphadoxine-pyrimethamine efficacy against Plasmodium falciparum eight years after deployment in eastern Sudan. Malar J 12:255. http://dx.doi.org/10.1186/1475-2875-12-255.
22. Gadalla NB, Adam I, Elzaki S-E, Bashir S, Mukhtar I, Oguike M, Gadalla A, Mansour F, Warhurst D, El-Sayed B, Sutherland CJ. 2011. Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether lumefantrine. Antimicrob Agents Chemother 55:5408-5411. http://dx.doi.org/10.1128/AAC.05102-11.
23. Nankabirwa JI, Wandera B, Amuge P, Kiwanuka N, Dorsey G, Rosenthal PJ, Brooker SJ, Staedke SG, Kamya MR. 2014. Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in ugandan schoolchildren: a randomized, placebo-controlled trial. Clin Infect Dis 58:1404-1412. http://dx.doi.org/10.1093/cid/ciu150.
24. Bigira V, Kapisi J, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Osterbauer B, Aweeka FT, Huang L, Achan J, Havlir DV, Rosenthal PJ, Kamya MR, Dorsey G. 2014. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med 11:e1001689. http://dx.doi.org/10.1371/journal.pmed.1001689.
25. Price RN, Hasugian AR, Ratcliff A, Siswantoro H, Purba HLE, Kenangalem E, Lindegardh N, Penttinen P, Laihad F, Ebsworth EP, Anstey NM, Tjitra E. 2007. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob Agents Chemother 51:4090-4097. http://dx.doi.org/10.1128/AAC.00486-07.
26. Creek DJ, Bigira V, McCormack S, Arinaitwe E, Wanzira H, Kakuru A, Tappero JW, Sandison TG, Lindegardh N, Nosten F, Aweeka FT, Parikh S. 2013. Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants. J Infect Dis 207:1646-1654. http://dx.doi.org/10.1093/infdis/jit078.
27. WHO. 1998. The use of artemisinin & its derivatives as anti-malarial drugs. Report of a Joint CTD/DMP/TDR Informal Consultation Geneva, 10-12 June 1998. WHO, Geneva, Switzerland. http://www.who.int/malaria/publications/atoz/who-mal-98-1086/en/.
28. Somé AF, Zongo I, Compaoré Y-D, Sakandé S, Nosten F, Ouédraogo J-B, Rosenthal PJ. 2014. Selection of drug resistance-mediating Plasmodium falciparum genetic polymorphisms by seasonal malaria chemoprevention in Burkina Faso. Antimicrob Agents Chemother 58:3660-3665. http://dx.doi.org/10.1128/AAC.02406-14.
29. Eastman RT, Dharia NV, Winzeler EA, Fidock DA. 2011. Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites. Antimicrob Agents Chemother 55:3908-3916. http://dx.doi.org/10.1128/AAC.01793-10.
30. Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, Lin K, Kyaw MP, Plewes K, Faiz MA, Dhorda M, Cheah PY, Pukrittayakamee S, Ashley EA, Anderson TJC, Shalini Nair S, McDew-White M, Flegg JA, Grist EPM, Guerin P, Maude RJ, Smithuis F, Dondorp AM, Day NPJ, Nosten F, White NJ, Woodrow CJ. 2015. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 15:415-421. http://dx.doi.org/10.1016/S1473-3099(15)70032-0.
31. White NJ, Olliari PL. 1996. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitol Today 12:399-401. http://dx.doi.org/10.1016/0169-4758(96)10055-7.
32. Lambert PC, Royston P. 2009. Further development of exible parametric models for survival analysis. Stata J 9:265-290.